Adrenal Myelolipoma: 372 Cases from A High-volume Center

Lede Lin
Institute of Urology (Laboratory of Reconstructive Urology), Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Lina Gong
Institute of Urology (Laboratory of Reconstructive Urology), Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Liang Zhou
Institute of Urology (Laboratory of Reconstructive Urology), Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Liang Cheng
Institute of Urology (Laboratory of Reconstructive Urology), Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Zhihong Liu
Institute of Urology (Laboratory of Reconstructive Urology), Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Sikui Shen
Institute of Urology (Laboratory of Reconstructive Urology), Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Yuchun Zhu (✉ mmaalleee@126.com)
Institute of Urology (Laboratory of Reconstructive Urology), Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

https://orcid.org/0000-0002-6140-2586

Research Article

Keywords: Adrenal myelolipoma, hypertension, surgery, remission, connections

DOI: https://doi.org/10.21203/rs.2.13870/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background. Adrenal myelolipoma (AML) is a non-functional benign neoplasm from adrenal cortex, composed of mature fat and hematopoietic tissue. Usually, patients have no symptoms. However, some present with hypertension and blood pressure normalizes after surgery, indicating some connections between AML and hypertension.

Materials and Methods. This is a retrospective cohort study of 372 patients diagnosed with AML from September 2008 to December 2018 collected in Urology Department of West China Hospital, Chengdu, Sichuan, China. We collected clinical records of patients before surgery. Postoperative follow-up was also done for those with hypertension and whether patients needed to take antihypertensive drugs and postoperative blood pressure were recorded. We aim to explore the characteristics of both AML patients with hypertension and remission of hypertension in 1 year after surgery.

Results. There were 372 AML patients included in the study, 159 males and 213 females, aged 49.77±11.64 years old. Among them, 118 patients presented with hypertension. The percentage of hypertension in each subgroup increased with age. Sixty patients were followed up for 1 to 9 years, with a median follow-up of 52 months. The course of hypertension in the remission group was shorter than that in the non-remission group (P=0.020), and tumor lateralization was significantly different between two groups (P=0.005).

Conclusion. Nearly one third of AML patients suffered from hypertension in our study and there do exist some potential links between AML and hypertension.

Introduction

Adrenal myelolipoma(AML) is generally considered a non-functional benign tumor originated from adrenal cortex, made up of variable proportion of mature fat and hematopoietic tissues (1). The number of case-reports about AML has considerably increased in recent years, which may be related to the development and wide application of imaging techniques, resulting in an increase in detection of adrenal incidentaloma including AML (2). Female patients are more common and the predilection age is 50-70 years old, with right lesions more prevalent than those in the left (1,3). Initially, the neoplasm is asymptomatic, which is discovered during routine physical examination accidentally. However, some are diagnosed with AML due to lumbar pain, abdominal pain, dizziness, abnormal level of hormones and so on (4-5). Some patients present with hypertension and are eventually diagnosed as AML by histopathological biopsy. There has been several reports on the normalized blood pressure following surgery of AML resection, suggesting that there may be a relationship between hypertension and AML (6-8). Hence, we aim to explore the characteristics of both AML patients with hypertension and remission of hypertension in 1 year after surgery.

Materials And Methods
Participants

This is a retrospective cohort study of 372 patients diagnosed with AML from September 2008 to December 2018 collected in Urology Department of West China Hospital, Chengdu, Sichuan, China. The study is approved by the Ethics Committee of West China Hospital of Sichuan University (IRB approval number 2019708). No informed consent for research is obtained from each individual because all the clinical records are acquired retrospectively from Hospital Inpatient System (HIS) when patients were admitted to hospital for diagnosis and treatment. All patients were treated with surgery.

Including and excluding criteria

The including criteria of this study were as follows: neoplasm from adrenal cortex presented by computer tomography (Figure 1); neoplasm more than 4 centimeters or complicated with hypertension or other symptoms; patients who underwent surgical removal of adrenal neoplasm; diagnosis of AML confirmed by pathological examination after surgery (Figure 2).

The excluding criteria of this study were as follows: diagnosis of other tumor by symptoms, laboratory examination and postoperative pathological examination, such as pheochromocytoma, primary aldosteronism and other adrenal diseases that may cause hypertension; AML patients combined with diseases detailed in ; patients with adrenal neoplasm that did not undergo a surgery.

Data

We collected clinical records of patients before surgery, consisting of gender, age, leading complaints (including lumbar pain and abdominal pain), history of diabetes, tumor lateralization, tumor diameter, body mass index (BMI), duration of hypertension, blood pressure and the number of antihypertensive drugs. Postoperative follow-up was also done for those with hypertension and whether patients needed to take antihypertensive drugs and postoperative blood pressure were recorded.

Group

All eligible patients were divided into two groups: hypertension and non-hypertension, based on the complication of hypertension (systolic blood pressure $\geq 140$ mmHg or diastolic blood pressure $\geq 90$ mmHg measured 3 times on different two days, or having started antihypertensive therapy). Based on the outcomes of follow-up, those with hypertension were divided into two groups: the remission group and the non-remission group. The remission of hypertension after the operation is defined as stopping the use of
antihypertensive drugs for 3 months and the blood pressure coming down to normal (< 140/90mmHg), which lasts till the end of follow-up.

**Statistical analysis**

All the procedures were finished on the statistical software, IBM SPSS Statistics 22. Discrete variables were reported as percentage, and continuous variables as mean± standard deviation (SD) or median (quartile). For analysis of categorical variables, Pearson χ² or Fisher Exact Test was used. Differences between means were tested with Student T test. Receiver operation characteristic (ROC) curve was utilized to examine the efficacy of a diagnostic model. P<0.05 was applied to certify the statistical significance between two groups of data. Normality of the distribution was tested using the Shapiro - Wilk test.

**Results**

**Characteristics of AML patients**

There were 372 eligible AML patients enrolled in our study, comprising of 159 males and 213 females. The average age was 49.77±11.64 years, among which 118 patients complicated with hypertension. The course of hypertension ranged from 1 days to 30 years and the mean systolic and diastolic pressure in hypertension group is 168.89±23.18 mmHg and 99.29±14.82 mmHg, respectively. Antihypertensive drugs included nifedipine, amlodipine, captopril, irbesartan, metoprolol, prazosin, furosemide and so on. The incidence of hypertension in AML is 31.7%.

**Characteristics of AML with hypertension**

Data were analyzed in subgroup of age and the demographic and clinical features were detailed in Table 1 and Supplement Table 1. We found that the percentage of hypertension in each subgroup increased with age. The lateralization in hypertension group was significantly different from that in non-hypertension group. However, there was no significant difference in tumor lateralization and tumor diameter in each subgroup, except for subgroup of age 20-29 and age 70-79.

**Characteristics of hypertension remission in 1 year after surgery**

Among 118 cases of AML complicated with hypertension, we finished following up 60 with follow-up time of 1-9 years. The median follow-up time was 52 months. There were 16 patients not using drugs in 1 year after operation, whose blood pressure returned to normal and continued till the end of the first year.
Three patients stopped taking antihypertensive drugs after operation, nonetheless, the blood pressure rose again in three weeks, 1 year and 2 years after operation, respectively, and their blood pressure was controlled well by taking antihypertensive drugs. While 43 patients needed to continue to take antihypertensive drugs after operation, and the blood pressure was well controlled. The number of antihypertensive drugs and level of blood pressure are not significantly different before and after surgery.

There was significant difference in the lateralization of tumor between the remission group and the non-remission group, with P value < 0.05. As for the course of hypertension, we utilized Wilcoxon rank sum test to ensure the inspection efficacy, proving that the statistical difference was significant. The remission rate was 26.67% in 1 year after the surgical treatment, while 22.22% (10 out of 45 cases) in 3 years, and 7 cases of 28 cases were with normal blood pressure value in the 5-year follow-up after operation. Cases with normal blood pressure had no further potential increase in blood pressure requiring antihypertensive medication.

ROC curve (Figure 3) was used to test the efficacy of course of hypertension to distinguish remission group from non-remission group in Table 2 and we were able to see the area under curve (AUC) is significant, with P value = 0.020. Thirteen out of 14 cases in remission group were of hypertension course no more than 3 years and the other one with 10 years of hypertension. The information in Table 3 showed that the cutoff of course of hypertension as \( \leq 3 \) years distinguished hypertension remission group from non-remission group, with sensitivity of 92.9% and specificity of 58.7%. The positive predictive value was 40.6% and the negative predictive value was 96.4%.

**Discussion**

In this study, we aim to explore characteristics of both AML patients with hypertension and remission of hypertension in 1 year after surgery. Based on our study, AML patients were usually diagnosed at the age of 49.77±11.64 on average, which is in consistence with the report of Decmann A (5) who reviewed 440 cases of AML with mean age of 51 ±14.4. The incidence of AML with hypertension in our study is 31.7%, while 22.3% of AML with hypertension was reported by Decmann A (5). It seems that there may exist some intrinsic connections between AML and hypertension.

On one hand, AML patients may be complicated with primary hypertension. In this study, we found that the proportion of hypertension in each subgroup in Supplement Table 1 increased with age, which is also a clinical risk characteristic of primary hypertension (9). If AML patients are complicated with primary hypertension, implying their blood pressure is not directly related to AML, the possibility of hypertension relief after operation will be low.
On the other hand, we found an interesting phenomenon in our research that more AML were located on the right side, with a proportion of 63.7%. Several studies (1,10-11) also reported this phenomenon. The cause of this phenomenon may be attributed to the pathogenesis of AML. Here comes a theory that adipose tissue originating from mesenchymal stem cells harbors in adrenal cortex and causes inflammatory reaction under certain stimulation, which is the first step in forming AML (12). In our human body, the right adrenal gland faces more possibility of friction from the inferior border of liver when we breath, which serves as a sort of stimuli contributing to the appearance of AML. However, the pathogenesis is even more complicated and perhaps involves with hormonal pathways. Further experimental data may reveal the the reason why there is a dominant right-sided AML.

In our study, we found that the important characteristics of hypertension remission in 1 year after surgery was the course of hypertension. The shorter the course of hypertension, the greater the possibility of blood pressure returning to normal after operation. After the lesion is surgically removed, compression effect on the kidney is relieved, and hypertension is alleviated. However, some patients' blood pressure did not return to normal, and we think, apart from primary hypertension, it may also be associated with the long duration of renal compression, leading to inflammation and promoting fibrosis, which causes irreversible damage to kidneys and blood vessels. Accordingly, blood pressure has not returned to a normal level after operation. However, we did not obtain all patients' hormone data in remission and non-remission group, before and after surgery. If the level of plasma renin activity goes down to normal after operation, our hypothesis will stand. In Table 3, we set a cutoff of ≤3 years to predict if AML with hypertension will relieve after operation. If a patient undergoes AML surgery, whose hypertension course is more than 3 years, his possibility of remission is relatively low, partially due to primary hypertension or the long duration of renal compression. Adequate cases with hormone data are needed to prove our idea and our study may provide some theoretical evidences.

Table 2 also presents a thought-provoking outcome. In the remission group, almost all cases (13/14) were from the right side. We discovered that the mean diameter of right-sided tumor in remission group was larger than that of left-side tumor in remission group, but not significantly. Was this phenomenon attributed to a lack of samples or some reasons like anatomical difference between left and right adrenal gland in our human body? We still do not know and more clinical and experimental data are needed.

Conclusions

Nearly one third of AML patients suffered from hypertension in our study and there do exist some potential links between AML and hypertension. To be more specific, AML patients with hypertension are likely to result from getting old and AML patient with hypertension more than 3 years is less likely to get
relieved. It is regretful this is a retrospective cohort study and there is a limit to the resources, so more further prospective studies are needed to explore and certify the results of our study.

List Of Abbreviations

Adrenal myelolipoma (AML)

Body mass index (BMI)

Standard deviation (SD)

Receiver operation characteristic (ROC)

Area under curve (AUC)

Declarations

Acknowledgements

None.

Authors Contributions Statement

Conception and design of study: L L and L G; Acquisition of data (laboratory or clinical): L L, L C, Z L and S S; Data analysis and/or interpretation: L L, L Z and L C; Drafting of manuscript and/or critical revision: L L, L Z, and Y Z; Approval of final version of manuscript: Y Z.

Conflict of Interest Statement

The authors declare that they have no competing interests.

Contribution to the Field Statement

Adrenal myelolipoma (AML) is a non-functional benign neoplasm from adrenal cortex, composed of mature fat and hematopoietic tissue. Usually, patients have no symptoms. However, some present with hypertension and blood pressure normalizes after surgery, indicating some connections between AML and hypertension. Hence, we aim to explore the characteristics of both AML patients with hypertension and remission of hypertension in 1 year after surgery. We enrolled 372 patients in this study, 159 males and 213 females, aged 49.77±11.64 years old. Among them, 118 patients presented with hypertension.
The percentage of hypertension in each subgroup increased with age. Sixty patients were followed up for 1 to 9 years, with a median follow-up of 52 months. The course of hypertension in the remission group was shorter than that in the non-remission group (P=0.020), and tumor lateralization was significantly different between two groups (P=0.005). In conclusion, nearly one third of AML patients suffered from hypertension in our study. AML patients with hypertension are likely to result from getting old and AML patient with hypertension more than 3 years is less likely to get relieved.

**Funding**

The work is supported by the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZY2016104), the Innovation Spark Project of Sichuan University (2018SCUH0061), the National Natural Science Fund of China (81800667).

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**References**

1. Lam Alfred King-Yin. Lipomatous tumours in adrenal gland: WHO updates and clinical implications. Endocr. Relat. Cancer, 2017, 24(3), R65-R79. doi:10.1530/ERC-16-0564
2. Yin Lei, Teng Jingfei, Zhou Qiwei, Liu Yushan, Yao Yacheng, Gao Yi., et al. A 10-year single-center experience with surgical management of adrenal myelolipoma. J. Endourol., 2014, 28(2), 252-5. doi:10.1089/end.2013.0283
3. Nabi Junaid, Rafiq Danish, Authoy Fatema N, Sofi Ghulam Nabi. Incidental detection of adrenal myelolipoma: a case report and review of literature. Case Rep Urol, 2013, 2013, 789481. doi:10.1155/2013/789481
4. Liu Hui-Pu, Chang Wen-Yen, Chien Shan-Tao, Hsu Chin-Wen, Wu Yu-Chiuan, Kung Wen-ching, et al. Intra-abdominal bleeding with hemorrhagic shock: a case of adrenal myelolipoma and review of literature. BMC Surg, 2017, 17(1), 74. doi:10.1186/s12893-017-0270-6
5. Decmann Ábel, Perge Pál, Tóth Miklós, Igaz Peter. Adrenal myelolipoma: a comprehensive review. Endocrine, 2018, 59(1), 7-15. doi:10.1007/s12020-017-1473-4
6. Udupa Sujatha, Usha M, Visweswara R N, Desai M G. Left-sided giant adrenal myelolipoma secreting catecholamine. Indian J Pathol Microbiol, 2012, 55(3), 389-91. doi:10.4103/0377-4929.101755
7. Tamidari Hema, Mishra Anand Kumar, Gupta Sushil, Agarwal Amit. Catecholamine secreting adrenal myelolipoma. Indian J Med Sci, 2006, 60(8), 331-3. doi:10.4103/0019-5359.26611
8. Jakka Nagendar, Venkateshwarlu J, Satyavani Naga, Neelaveni K, Ramesh Jayanthy. Functioning adrenal myelolipoma: A rare cause of hypertension. Indian J Endocrinol Metab, 2013, 17, S249-51. doi:10.4103/2230-8210.119588

9. Chen Wei-Wei, Gao Run-Lin, Liu Li-Sheng, Zhu Man-Lu, Wang Wen, Wang Yong-Jun, et al. China cardiovascular diseases report 2015: a summary. J Geriatr Cardiol, 2017, 14(1), 1-10. doi:10.11909/j.issn.1671-5411.2017.01.012

10. Shenoy Vasanth G, Thota Anuroop, Shankar Ravi, Desai Mallikarjun G. Adrenal myelolipoma: Controversies in its management. Indian J Urol, 2015, 31(2), 94-101. doi:10.4103/0970-1591.152807

11. Lam Alfred King-Yin. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr. Pathol., 2017, 28(3), 213-227. doi:10.1007/s12022-017-9484-5

12. Feng Chenchen, Jiang Haowen, Ding Qiang, Wen Hui. Adrenal myelolipoma: a mingle of progenitor cells? Med. Hypotheses, 2013, 80(6), 819-22. doi:10.1016/j.mehy.2013.03.021

Tables

Table 1. Characteristics of AML patients with hypertension

| Demographic and clinical features | Hypertension | Non-hypertension | P value |
|----------------------------------|--------------|------------------|--------|
| Number of cases(%)              | 118 (31.7%)  | 254 (68.3%)      |        |
| Mean age ± SD, years            | 54.97 ±10.18 | 47.36 ±11.50     | <0.001 |
| Sex, males/females              | 53/65        | 106/148          | 0.564  |
| Leading complaints (%)          | 23 (19.5%)   | 47 (18.5%)       | 0.821  |
| Diabetes mellitus (%)           | 16 (13.6%)   | 19 (7.5%)        | 0.062  |
| Tumor location, left/right/bilateral | 52/66/0     | 78/171/5         | 0.009  |
| Mean tumor diameter ± SD, cm    | 6.10±3.04    | 5.80±2.86        | 0.352  |

AML: adrenal myelolipoma; SD: standard deviation

Leading complaints include lumbar pain and abdominal pain.

Table 2. Characteristics of hypertension in 1 year after surgery
| Demographic and clinical features | Remission | Non-remission | P value |
|----------------------------------|-----------|--------------|---------|
| Number of cases(%)               | 14#(23.3%)| 46(76.7%)    |         |
| Mean age ± SD, years             | 54.14±10.01| 54.89±10.09 | 0.809   |
| Sex, males/females               | 7/7       | 17/29        | 0.535   |
| Mean BMI ± SD, kg/m²             | 24.95±2.32| 25.86±3.63   | 0.273   |
| Leading complaints(%)            | 2(14.3%)  | 6(13.0%)     | 1.000   |
| Median course of hypertension (quartile), d | 272.5 (52.5,730) | 1642.5 (225,3011.25) | 0.020 |
| Tumor location, left/right       | 1/13      | 23/23        | 0.005   |
| Mean left-sided tumor diameter ± SD, cm | 3       | 5.82± 2.11   | 0.204   |
| Mean right-sided tumor diameter ± SD, cm | 5.55 ±2.51 | 6.23± 3.38 | 0.534 |

SD: standard deviation; BMI: body mass index

Leading complaints include lumbar pain and abdominal pain.

#: There were actually 16 cases in the remission group, however, the blood pressure in two of them rose again in 1 year and 2 years after operation, respectively. Therefore, we put those two cases in the non-remission group.

Table 3. Evaluation of course of hypertension (≤3 years as a cutoff)

|                  | Remission | Non-remission | Total number |
|------------------|-----------|--------------|--------------|
| ≤3 years         | 13        | 19           | 32           |
| ≥3 years         | 1         | 27           | 28           |
| Total number     | 14        | 46           | 60           |

Supplement Table 1. Characteristics of AML patients with hypertension
| Demographic and clinical features | Hypertension | Non-hypertension | P value |
|----------------------------------|--------------|------------------|---------|
| Number of cases(%)              | 118(31.7%)   | 254(68.3%)       |         |
| Age 20-29, n=22                  | 1            | 21               |         |
| Mean age ± SD, years             | 29           | 26.38 ±2.11      |         |
| Sex, males/females               | 1/0          | 12/9             |         |
| Leading complaints(%)            | 0            | 7(33.3%)         |         |
| Diabetes mellitus(%)             | 0            | 0                |         |
| Tumor location, left/right/bilateral | 1/0/0    | 4/17/0           |         |
| Mean tumor diameter ± SD, cm     | 3            | 5.69±3.43        |         |
| Age 30-39, n=41                  | 4            | 37               |         |
| Mean age ± SD, years             | 34.50±2.65   | 34.70±3.17       | 0.903   |
| Sex, males/females               | 4/0          | 15/22            | 0.038   |
| Leading complaints(%)            | 1(25.0%)     | 4(10.8%)         | 0.418   |
| Diabetes mellitus(%)             | 0            | 2(5.4%)          | 1.000   |
| Tumor location, left/right/bilateral | 1/3/0    | 6/31/0           | 0.542   |
| Mean tumor diameter ± SD, cm     | 5.13±2.25    | 5.87±2.80        | 0.612   |
| Age 40-49, n=122                 | 35           | 87               |         |
| Mean age ± SD, years             | 45.60±2.78   | 44.63±2.79       | 0.085   |
| Sex, males/females               | 19/16        | 40/47            | 0.406   |
| Leading complaints(%)            | 9(25.7%)     | 18(20.7%)        | 0.545   |
| Diabetes mellitus(%)             | 3(8.6%)      | 2(2.3%)          | 0.142   |
| Tumor location, left/right/bilateral | 13/22/0   | 23/61/3          | 0.306   |
| Mean tumor diameter ± SD, cm     | 6.39±3.50    | 5.63±2.67        | 0.193   |
| Age 50-59, n=104                 | 33           | 71               |         |
| Mean age ± SD, years             | 53.79±3.03   | 53.89±2.77       | 0.869   |
| Sex, males/females               | 14/19        | 27/44            | 0.669   |
| Leading complaints(%)            | 5(15.2%)     | 12(16.9%)        | 0.822   |
| Diabetes mellitus(%)             | 4(12.1%)     | 8(11.3%)         | 1.000   |
| Tumor location, left/right/bilateral | 13/20/0   | 25/43/3          | 0.472   |
|                                | Mean tumor diameter ± SD, cm | Mean age ± SD, years | Sex, males/females | Leading complaints(%) | Diabetes mellitus(%) | Tumor location, left/right/bilateral | Mean tumor diameter ± SD, cm |
|--------------------------------|-----------------------------|----------------------|--------------------|-----------------------|----------------------|-------------------------------------|-----------------------------|
|                                | 5.81±2.77                   | 6.07±3.27            | 34                 | 34                    |                      |                                     | 0.686                       |
| Age 60-69, n=68                |                             |                      |                    |                       |                      |                                     |                             |
| Mean age ± SD, years           | 63.12±2.56                  | 64.32±3.22           |                    |                       |                      |                                     | 0.092                       |
| Sex, males/females             | 11/23                       | 12/22                |                    |                       |                      |                                     | 0.798                       |
| Leading complaints(%)          | 9(26.5%)                    | 6(17.6%)             |                    |                       |                      |                                     | 0.380                       |
| Diabetes mellitus(%)           | 6(17.6%)                    | 5(14.7%)             |                    |                       |                      |                                     | 0.742                       |
| Tumor location, left/right/bilateral | 18/16/0                   | 17/17/0              |                    |                       |                      |                                     | 0.808                       |
| Mean tumor diameter ± SD, cm   | 6.37±3.24                   | 5.32±1.99            |                    |                       |                      |                                     | 0.114                       |
| Age 70-79, n=15                | 72.91±2.43                  | 73.75±3.59           |                    |                       |                      |                                     | 0.608                       |
| Sex, males/females             | 4/7                         | 0/4                  |                    |                       |                      |                                     | 0.516                       |
| Leading complaints(%)          | 2(18.2%)                    | 1(25.0%)             |                    |                       |                      |                                     | 1.000                       |
| Diabetes mellitus(%)           | 3(27.3%)                    | 2(50.0%)             |                    |                       |                      |                                     | 0.560                       |
| Tumor location, left/right/bilateral | 6/5/0                    | 3/1/0                |                    |                       |                      |                                     | 0.604                       |
| Mean tumor diameter ± SD, cm   | 5.82±1.90                   | 8.33±2.15            |                    |                       |                      |                                     | 0.047                       |

AML: adrenal myelolipoma; SD: standard deviation

Leading complaints include lumbar pain and abdominal pain.